20161122_mc2-portrait-02

Release your
full potential

Be active. Be free. Experience real-life
superior treatment with PADTM Technology based drugs.

ABOUT US

MC2 Therapeutics is a privately held emerging dermatology and eye care pharmaceutical company. Read more about MC2 Therapeutics.

Platform

Our PAD™ Technology is a new class of vehicle that enables development of new topical drugs with superior real-life performance. Read more about our platform.

Pipeline

Our current pipeline includes programs in major chronic topical diseases such as psoriasis, atopic dermatitis, pruritus and dry and sensitive skin and eyes. Read more about our pipeline.

LATEST NEWS

MC2 Therapeutics A/S announces first patient dosed in pivotal US Phase 3 trial in psoriasis vulgaris

  • First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of ...

    READ FULL ARTICLE

MC2 Therapeutics A/S appoints Anders D. Hove and Paul L. Berns to the Board of Directors

Copenhagen, August, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, has ...

READ FULL ARTICLE

 

MC2 Therapeutics to present data at the 2017 ARVO Annual Meeting highlighting the therapeutic potential of PAD® Techno.

Copenhagen, February 24th, 2017 – MC2 Therapeutics today announced that two abstracts were accepted for ...

READ FULL ARTICLE

MC2 Biotek becomes MC2 Therapeutics

MC2 Biotek, a clinical stage emerging specialty pharmaceutical company focusing on dermatology and ophthalmology, today ...

READ FULL ARTICLE

© mc2 therapeautics 2016